Q1 EPS Estimates for Vivani Medical Boosted by HC Wainwright

Vivani Medical, Inc. (NASDAQ:VANI) – Equities researchers at HC Wainwright upped their Q1 2026 earnings estimates for Vivani Medical in a note issued to investors on Tuesday, March 31st. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of ($0.08) per share for the quarter, up from their previous forecast of ($0.09). HC Wainwright currently has a “Buy” rating and a $3.50 target price on the stock. The consensus estimate for Vivani Medical’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Vivani Medical’s Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.07) EPS and FY2026 earnings at ($0.30) EPS.

Vivani Medical (NASDAQ:VANI) last released its quarterly earnings data on Thursday, March 26th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Vivani Medical in a research report on Friday, January 9th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $3.50.

Vivani Medical Price Performance

NASDAQ:VANI opened at $1.08 on Friday. Vivani Medical has a 1 year low of $0.91 and a 1 year high of $1.92. The stock’s fifty day moving average price is $1.21 and its two-hundred day moving average price is $1.35. The company has a market cap of $91.42 million, a P/E ratio of -2.51 and a beta of 2.16.

Institutional Trading of Vivani Medical

Institutional investors have recently made changes to their positions in the stock. Tudor Investment Corp ET AL purchased a new position in shares of Vivani Medical during the 4th quarter worth $1,127,000. Geode Capital Management LLC raised its holdings in Vivani Medical by 29.6% in the 4th quarter. Geode Capital Management LLC now owns 461,652 shares of the company’s stock worth $568,000 after purchasing an additional 105,398 shares during the period. State Street Corp raised its holdings in Vivani Medical by 12.5% in the 4th quarter. State Street Corp now owns 144,865 shares of the company’s stock worth $178,000 after purchasing an additional 16,070 shares during the period. Marshall Wace LLP purchased a new position in Vivani Medical during the fourth quarter valued at $174,000. Finally, Renaissance Technologies LLC lifted its position in Vivani Medical by 118.4% during the fourth quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock valued at $121,000 after purchasing an additional 53,127 shares in the last quarter. Hedge funds and other institutional investors own 6.78% of the company’s stock.

Insider Buying and Selling

In other Vivani Medical news, Director Gregg Williams bought 1,575,231 shares of Vivani Medical stock in a transaction on Sunday, March 15th. The stock was acquired at an average price of $1.07 per share, with a total value of $1,685,497.17. Following the acquisition, the director owned 31,357,183 shares in the company, valued at approximately $33,552,185.81. This trade represents a 5.29% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders acquired 4,664,347 shares of company stock worth $5,666,549. Company insiders own 46.40% of the company’s stock.

Vivani Medical Company Profile

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.